Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

INTRODUCTION: Immune checkpoint inhibitors (ICIs) can lead to immune-related adverse events (irAEs). A correlation between the development of irAEs and efficacy has been suggested; however, it is unclear whether there is a relationship between programmed death ligand 1 (PD-L1) expression and the dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugisaka, Jun, Toi, Yukihiro, Taguri, Masataka, Kawashima, Yosuke, Aiba, Tomoiki, Kawana, Sachiko, Saito, Ryohei, Aso, Mari, Tsurumi, Kyoji, Suzuki, Kana, Shimizu, Hisashi, Ono, Hirotaka, Domeki, Yutaka, Terayama, Keisuke, Nakamura, Atsushi, Yamanda, Shinsuke, Kimura, Yuichiro, Honda, Yoshihiro, Sugawara, Shunichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Medical Association 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733761/
https://www.ncbi.nlm.nih.gov/pubmed/33324776
http://dx.doi.org/10.31662/jmaj.2019-0005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733761/
https://www.ncbi.nlm.nih.gov/pubmed/33324776
http://dx.doi.org/10.31662/jmaj.2019-0005

Ejemplares similares